

UROLOGY


AT YALE | 2020

Inside Urology at Yale

Issue 23 | March 2020

HIGHLIGHTS

UROLOGY AT YALE | 2020 IS NOW AVAILABLE



The third edition of *Urology at Yale* is now available. In this issue, we feature **Jaime Cavallo, MD, MPHS**, and a profile on her approach to reconstructive genitourinary surgery for male patients; **Daniel Petrylak, MD**, and his impact not only on patients with prostate and bladder cancers, but also as a mentor to other physicians and scientists; **Daniel Kellner, MD**, and the impact the HoLEP procedure is having on his patients; **John Onofrey, PhD**, is improving prostate biopsies through the use of machine learning and artificial intelligence; As the head of the **Urology Advisory Group**, Michael Silverberg leads efforts to fund the projects and research of department faculty; and the **Telehealth** program offers patients the opportunity to have their post-op appointment conducted from the comfort of their own home through their computer or smart device.

Please click [here](#) to read the magazine. If you would like to request print copies, please contact [Eliza Folsom](#).

DOXIMITY VOTING NOW OPEN

Voting is now open through [Doximity](#) for *U.S. News & World Report's* annual Best Hospitals Guide. If you have not yet voted, please take a moment to login to your profile and share your support for Yale New Haven Hospital. It is important that our reputation through *U.S. News & World Report's* annual Best Hospitals Guide reflects the high level of care Yale Urology provides to our patients, and represents the exciting research happening here.



To vote:

- Log in to your account on [Doximity](#).
- Click on the Best Hospital survey on the top of the page.
- You will then be asked to: *Name up to five U.S. hospitals that you believe provide the best care in urology for patients who have the most challenging conditions or who need particularly difficult procedures. **Please submit your response for Yale New Haven Hospital.***

If you have questions or do not have an opportunity to vote, contact Doximity at support@doximity.com.

OPENNOTES TO BE LAUNCHED SOON WITHIN EPIC



Yale Medicine is launching **OpenNotes**, a new functionality in EPIC, which will enable patients to view the notes and documentation from our providers within the MyChart portal. OpenNotes is an initiative led by Yale Medicine and Yale New Haven Health System and it aligns with several core principles including: Supporting a culture of transparency;

building trust between the patient and his or her provider; reminding and reinforcing visit messages; and facilitating patient access to their medical records.

OpenNotes is expected to launch soon within all Urology clinics, and will be accessible by patients using the MyChart web portal only; it is not available using the MyChart app at this time.

For information about this initiative, please visit [OpenNotes.org](#). We will discuss questions and concerns regarding this initiative during the next Urology Faculty Meeting, Monday, March 16 at 6:00 p.m. in the Urology Administrative Suite (FMP 300).

LAURIE EVANS NAMED WESTERLY HOSPITAL EMPLOYEE OF THE MONTH



Urology Assistant, **Laurie Evans**, based in the Yale Urology clinic at Westerly Hospital, was named January 2020 Employee of the Month for Westerly Hospital. The honor was presented to Laurie by Westerly Hospital President and CEO, Patrick Green, and Mike Southwell, director, leadership and organizational development.


As a Urology Assistant, Laurie is the back bone of the office. Among her daily responsibilities, she escorts patients to their exam room, takes vital signs, sets up for procedures, and also orders special items and ensures everyone working in the clinic has what they need.

Congratulations, Laurie!

PETER SCHULAM REPRESENTS YALE UROLOGY AT YALE MEDICINE DISCOVERS EVENT

Peter Schulam, MD, PhD was one of six faculty from Yale School of Medicine to present at Yale Medicine Discovers, a symposium hosted by Edward and Nancy Madden in Palm Beach, Florida. Along with Matthew Ellman, MD, David Hafler, MD, Roy Herbst, MD, PhD, David Leffell, MD, and Elena Ratner,

MD, Dr. Schulam shared updates on advances in patient care and research from Urology to a large group of Yale alumni and friends.



Pictured (left - right): David Leffell, MD, Roy Herbst, MD, PhD, Matthew Ellman, MD, Elena Ratner, MD, David Hafler, MD, Emily Corvino, Tamiko Collier, Peter Schulam, MD, PhD

CLINICAL TRIAL NEWS

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

Principal Investigator: [Joseph Kim, MD](#)

This phase I/II trial studies the best dose and side effects of olaparib and how well it works with radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to the bone and other places in the body (metastatic). [Learn more>>](#)

A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

Principal Investigator: [Joseph Kim, MD](#)

This phase I/II trial studies the side effects and best dose of tazemetostat and how well it works when given together with pembrolizumab in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes or other places in the body (locally advanced/metastatic). [Learn more>>](#)

A Phase 2 Study of M6620 in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: [Joseph Kim, MD](#)

This phase II trial studies how well ATR kinase inhibitor M6620 and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). [Learn more>>](#)

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (WIRB)

Principal Investigator: [Daniel Petrylak, MD](#)

The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma. Sitravatinib selectively inhibits key molecular and cellular pathways strongly implicated in checkpoint inhibitor resistance and therefore represents a rational strategy to enhance or restore anti-tumor immunity when combined with nivolumab, a checkpoint inhibitor therapy. [Learn more>>](#)

PUBLICATIONS

[When and How Should Active Surveillance for Prostate Cancer be De-Escalated?](#)

Rajwa P, Sprenkle PC, Leapman MS.
Eur Urol Focus. 2020 Feb 1.

[Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening.](#)

Yang DX, Makarov DV, Gross CP, Yu JB.
Cancer Control. 2020 Jan-Dec.

[Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.](#)

Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J.
J Pediatr Urol. 2019 Dec 27.

[Chasing the Pack: Association between Urology Hospital Rankings and Surgical Outcome.](#)

Abello A, Leapman M, Kenney PA.
J Urol. 2019 Dec 20.

UPCOMING EVENTS

CONFERENCES

[13th Annual Interdisciplinary Prostate Cancer Congress®](#)

March 13-14, 2020 | New York, NY

[AUA2020](#)

May 15-18, 2020 | Washington, D.C.

HAPPENINGS

Save the Date: Yale Urology Alumni Reception at AUA2020

May 16, 2020 | 4:00 p.m. - 6:00 p.m. | Conrad, Washington, DC | [RSVP](#)

Do you have any news, publications, or photos to share for an upcoming issue?



Please share with Eliza Folsom,
Assoc. Communications Officer
for Yale Urology:

eliza.folsom@yale.edu

Yale Medicine
UROLOGY

YaleNewHavenHealth
Yale New Haven Hospital